280 related articles for article (PubMed ID: 22905718)
1. Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation.
Yang J; Cheuk DK; Ha SY; Chiang AK; Lee TL; Ho MH; Chan GC
Pediatr Transplant; 2012 Nov; 16(7):771-8. PubMed ID: 22905718
[TBL] [Abstract][Full Text] [Related]
2. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody.
Kobbe G; Schneider P; Rohr U; Fenk R; Neumann F; Aivado M; Dietze L; Kronenwett R; Hünerlitürkoglu A; Haas R
Bone Marrow Transplant; 2001 Jul; 28(1):47-9. PubMed ID: 11498743
[TBL] [Abstract][Full Text] [Related]
3. Infliximab treatment for steroid-refractory acute graft-versus-host disease.
Patriarca F; Sperotto A; Damiani D; Morreale G; Bonifazi F; Olivieri A; Ciceri F; Milone G; Cesaro S; Bandini G; Dini G; Corradini P; Fanin R
Haematologica; 2004 Nov; 89(11):1352-9. PubMed ID: 15531458
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
5. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease.
Rao K; Rao A; Karlsson H; Jagani M; Veys P; Amrolia PJ
J Pediatr Hematol Oncol; 2009 Jun; 31(6):456-61. PubMed ID: 19648797
[TBL] [Abstract][Full Text] [Related]
6. [Anti-CD25 monoclonal antibody with antithymocytic globulin for steroid-resistant severe acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation].
Ye CX; Sun J; Liu QF; Qu H; Xu D; Zhang Y; Meng FY
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Dec; 28(12):2224-6. PubMed ID: 19114364
[TBL] [Abstract][Full Text] [Related]
7. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of children treated with daclizumab for steroid-refractory gastrointestinal GvHD in a prospective study.
Hamidieh AA; Hadjibabaie M; Ghehi MT; Jalili M; Hosseini A; Pasha F; Behfar M; Ghavamzadeh A
Pediatr Transplant; 2012 Sep; 16(6):664-9. PubMed ID: 22738324
[TBL] [Abstract][Full Text] [Related]
9. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
10. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S
Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.
Gómez-Almaguer D; Ruiz-Argüelles GJ; del Carmen Tarín-Arzaga L; González-Llano O; Gutiérrez-Aguirre H; Cantú-Rodríguez O; Jaime-Pérez J; Carrasco-Yalán A; Giralt S
Biol Blood Marrow Transplant; 2008 Jan; 14(1):10-5. PubMed ID: 18158956
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic transplantation of peripheral blood progenitor cells in children: experience of two pediatric centers.
Miniero R; Busca A; Bonetti F; Giorgiani G; Zecca M; Berger M; Incarbone E; Vassallo E; Perotti C; Locatelli F
Bone Marrow Transplant; 1998 Dec; 22 Suppl 5():S33-6. PubMed ID: 9989887
[TBL] [Abstract][Full Text] [Related]
14. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.
Wolff D; Roessler V; Steiner B; Wilhelm S; Weirich V; Brenmoehl J; Leithaeuser M; Hofmeister N; Junghanss C; Casper J; Hartung G; Holler E; Freund M
Bone Marrow Transplant; 2005 May; 35(10):1003-10. PubMed ID: 15806135
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.
Kobos R; Steinherz PG; Kernan NA; Prockop SE; Scaradavou A; Small TN; Shukla N; Khalaf R; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2012 Mar; 18(3):473-80. PubMed ID: 22079789
[TBL] [Abstract][Full Text] [Related]
16. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin.
Khoury H; Kashyap A; Adkins DR; Brown RA; Miller G; Vij R; Westervelt P; Trinkaus K; Goodnough LT; Hayashi RJ; Parker P; Forman SJ; DiPersio JF
Bone Marrow Transplant; 2001 May; 27(10):1059-64. PubMed ID: 11438821
[TBL] [Abstract][Full Text] [Related]
17. Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience.
Miano M; Cuzzubbo D; Terranova P; Giardino S; Lanino E; Morreale G; Castagnola E; Dini G; Faraci M
Bone Marrow Transplant; 2009 Mar; 43(5):423-7. PubMed ID: 18850021
[TBL] [Abstract][Full Text] [Related]
18. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
19. [Clinical analysis of 104 patients with hematological malignancy after allogeneic hemotopoietic stem cell transplantation].
Chen Y; Xu Y; Zhu Y; Fu G; Liu Y; Peng J; Fu B; He Q; Wu D; Li X; Zhao X; Chen F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Sep; 36(9):859-64. PubMed ID: 21946205
[TBL] [Abstract][Full Text] [Related]
20. Infliximab for GVHD therapy in children.
Sleight BS; Chan KW; Braun TM; Serrano A; Gilman AL
Bone Marrow Transplant; 2007 Sep; 40(5):473-80. PubMed ID: 17618323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
